Home
About
FAQ
History (5)
A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis.
Association analysis in african americans of European-derived type 2 diabetes single nucleotide polymorphisms from whole-genome association studies.
Difference in vasoconstrictors: oxymetazoline vs. brimonidine.
Off-label prescribing in the treatment of dermatologic disease.
Race-specific relationships between coronary and carotid artery calcification and carotid intimal medial thickness.
See All 5 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Difference in vasoconstrictors: oxymetazoline vs. brimonidine.
Okwundu N, Cline A, Feldman SR. Difference in vasoconstrictors: oxymetazoline vs. brimonidine. J Dermatolog Treat. 2021 Mar; 32(2):137-143.
View in:
PubMed
subject areas
Administration, Topical
Clinical Trials as Topic
Dermatitis
Erythema
Humans
Oxymetazoline
Rosacea
Treatment Outcome
Vasoconstrictor Agents
authors with profiles
Steven R. Feldman MD, PhD